The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.
Bevacizumab
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to predict degrees of patient response. CME This article is available for continuing medical education credit at CME.TheOncologist.com.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It acts by binding and circulating the VEGF and preventing binding to the VEGF receptor, which prevents angiogenesis [45].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Research works printed but not linked: 6
- U. S. Food and Drug Administration, Center for Drug Evaluation and Research. Final Labeling Text, BL125085 Supplement, 2008
- The European Medicines Agency, European Public Assessment Report. Avastin Product Information. Avastin-H-C-582-II-23, August 2008
- Pegram, 2006, Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract S28], Breast Cancer Res Treat, 100, S28
- Gaudreault, 2001, Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC), Clin Pharmacol Ther, 69, 25
- U. S. Food and Drug Administration, Center for Drug Evaluation and Research. 2008 Safety Alerts for Human Medical Products. Dear Healthcare Professional Letter - Genentech
- National Institute for Health and Clinical Excellence, TA118 Colorectal Cancer (Metastatic) – Bevacizumab & Cetuximab: Guidance; January 2007
Cited by
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35431-x · Cited by 253
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Trial watch: IDO inhibitors in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 187
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Safri, F., Nguyen, R., Zerehpooshnesfchi, S., George, J., & Qiao, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00764-w · Cited by 162
Metadata
- Authors
- Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M.
- Affiliations
- Utrecht University (NL)
- Corresponding author
- Schellens, Jan H. M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-08-01
- Volume
- 15
- Issue
- 8
- Pages
- 819-825
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3228024
- OpenAlex
- W4234401042
- Cited by
- 291
- References
- 41
- Citations by year
- 2026: 19 · 2025: 35 · 2024: 45 · 2023: 51 · 2022: 44 · 2021: 38 · 2020: 21 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 1 · 2013: 6 · 2012: 4
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- bevacizumab, anti-VEGF therapy, cancer therapy, combination chemotherapy, mechanism of action, treatment response prediction
- MeSH terms
- Bevacizumab, Animals, Antibodies, Monoclonal, Humans, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bevacizumab. https://app.cochat.ai/papers/10.1634/theoncologist.2009-0317
- The paper
- Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010). Bevacizumab. The Oncologist. https://doi.org/10.1634/theoncologist.2009-0317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.